Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma, Aspirin-Induced | 1 | 2021 | 7 | 0.760 |
Why?
|
Head Injuries, Penetrating | 1 | 2020 | 6 | 0.710 |
Why?
|
Cerebrovascular Trauma | 1 | 2020 | 6 | 0.710 |
Why?
|
Cerebral Intraventricular Hemorrhage | 1 | 2020 | 3 | 0.710 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2020 | 101 | 0.660 |
Why?
|
Aspirin | 2 | 2021 | 392 | 0.640 |
Why?
|
Agammaglobulinemia | 1 | 2018 | 50 | 0.640 |
Why?
|
Aneurysm, False | 1 | 2020 | 143 | 0.620 |
Why?
|
Immunity, Humoral | 1 | 2018 | 88 | 0.610 |
Why?
|
Hydrocephalus | 1 | 2020 | 260 | 0.580 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 544 | 0.580 |
Why?
|
Peanut Hypersensitivity | 3 | 2024 | 71 | 0.550 |
Why?
|
Community-Acquired Infections | 1 | 2018 | 286 | 0.540 |
Why?
|
Neurosurgical Procedures | 1 | 2020 | 634 | 0.490 |
Why?
|
Embolization, Therapeutic | 1 | 2020 | 606 | 0.470 |
Why?
|
Desensitization, Immunologic | 3 | 2024 | 104 | 0.420 |
Why?
|
Arachis | 2 | 2024 | 71 | 0.410 |
Why?
|
Pneumonia | 1 | 2018 | 798 | 0.410 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2021 | 3392 | 0.350 |
Why?
|
Mass Screening | 1 | 2018 | 1547 | 0.350 |
Why?
|
Hypersensitivity | 2 | 2021 | 221 | 0.310 |
Why?
|
Immunoglobulin G | 2 | 2021 | 1140 | 0.260 |
Why?
|
Telemedicine | 3 | 2021 | 549 | 0.250 |
Why?
|
Allergens | 3 | 2024 | 252 | 0.240 |
Why?
|
Infusions, Subcutaneous | 2 | 2021 | 14 | 0.230 |
Why?
|
Coronavirus Infections | 2 | 2020 | 633 | 0.200 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 709 | 0.200 |
Why?
|
Pneumococcal Vaccines | 2 | 2021 | 184 | 0.200 |
Why?
|
Nasal Polyps | 1 | 2020 | 28 | 0.180 |
Why?
|
Diphenhydramine | 1 | 2020 | 20 | 0.180 |
Why?
|
Remote Consultation | 1 | 2020 | 37 | 0.180 |
Why?
|
Rhinitis | 1 | 2020 | 40 | 0.180 |
Why?
|
Allergy and Immunology | 1 | 2020 | 30 | 0.180 |
Why?
|
Nut Hypersensitivity | 1 | 2019 | 7 | 0.170 |
Why?
|
Occupational Injuries | 1 | 2020 | 16 | 0.170 |
Why?
|
Ventriculostomy | 1 | 2020 | 42 | 0.170 |
Why?
|
Nuts | 1 | 2019 | 16 | 0.170 |
Why?
|
Appointments and Schedules | 1 | 2020 | 97 | 0.170 |
Why?
|
Central Nervous System Cysts | 1 | 2019 | 16 | 0.170 |
Why?
|
Cerebral Angiography | 1 | 2020 | 148 | 0.170 |
Why?
|
Epidermal Cyst | 1 | 2019 | 47 | 0.170 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2021 | 255 | 0.170 |
Why?
|
Dermoid Cyst | 1 | 2019 | 39 | 0.160 |
Why?
|
Craniopharyngioma | 1 | 2019 | 56 | 0.160 |
Why?
|
Drug Hypersensitivity | 1 | 2020 | 134 | 0.160 |
Why?
|
Epinephrine | 1 | 2020 | 249 | 0.160 |
Why?
|
Immune Tolerance | 1 | 2021 | 431 | 0.160 |
Why?
|
Anaphylaxis | 1 | 2020 | 123 | 0.160 |
Why?
|
Patient Satisfaction | 2 | 2021 | 916 | 0.150 |
Why?
|
Craniotomy | 1 | 2020 | 304 | 0.150 |
Why?
|
Drainage | 1 | 2020 | 448 | 0.140 |
Why?
|
Pituitary Neoplasms | 1 | 2019 | 218 | 0.140 |
Why?
|
Pandemics | 3 | 2021 | 1606 | 0.140 |
Why?
|
Rituximab | 1 | 2020 | 1588 | 0.120 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2020 | 1068 | 0.110 |
Why?
|
Male | 10 | 2024 | 128957 | 0.100 |
Why?
|
Length of Stay | 1 | 2018 | 2015 | 0.100 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2020 | 1335 | 0.090 |
Why?
|
Prospective Studies | 3 | 2021 | 13400 | 0.090 |
Why?
|
Telephone | 2 | 2021 | 160 | 0.090 |
Why?
|
Humans | 15 | 2024 | 271884 | 0.080 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 2474 | 0.080 |
Why?
|
Administration, Oral | 2 | 2024 | 1620 | 0.080 |
Why?
|
Adult | 5 | 2021 | 81857 | 0.080 |
Why?
|
Female | 9 | 2024 | 149143 | 0.080 |
Why?
|
Time Factors | 1 | 2020 | 13130 | 0.070 |
Why?
|
Betacoronavirus | 2 | 2020 | 522 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 7790 | 0.060 |
Why?
|
Diphtheria Toxoid | 1 | 2021 | 13 | 0.050 |
Why?
|
Diphtheria | 1 | 2021 | 16 | 0.050 |
Why?
|
Tetanus Toxoid | 1 | 2021 | 50 | 0.050 |
Why?
|
Tetanus | 1 | 2021 | 23 | 0.050 |
Why?
|
Serogroup | 1 | 2021 | 59 | 0.050 |
Why?
|
Aged | 4 | 2021 | 73471 | 0.050 |
Why?
|
Risk Factors | 1 | 2018 | 18045 | 0.050 |
Why?
|
Electronics | 1 | 2020 | 63 | 0.040 |
Why?
|
Mouthwashes | 1 | 2020 | 42 | 0.040 |
Why?
|
Public Health Surveillance | 1 | 2019 | 64 | 0.040 |
Why?
|
Office Visits | 1 | 2020 | 95 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2020 | 344 | 0.040 |
Why?
|
Skin Tests | 1 | 2019 | 102 | 0.040 |
Why?
|
Streptococcus pneumoniae | 1 | 2021 | 404 | 0.040 |
Why?
|
Immunoglobulin E | 1 | 2019 | 181 | 0.040 |
Why?
|
RNA, Viral | 1 | 2021 | 729 | 0.040 |
Why?
|
Outpatients | 1 | 2020 | 469 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2021 | 720 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2020 | 534 | 0.030 |
Why?
|
Infant | 2 | 2024 | 13931 | 0.030 |
Why?
|
Middle Aged | 5 | 2021 | 90395 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2021 | 3539 | 0.030 |
Why?
|
Child, Preschool | 2 | 2024 | 16999 | 0.030 |
Why?
|
Chronic Disease | 1 | 2020 | 1849 | 0.030 |
Why?
|
Inpatients | 1 | 2020 | 695 | 0.030 |
Why?
|
Sex Factors | 1 | 2020 | 2206 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2020 | 940 | 0.030 |
Why?
|
Disease Management | 1 | 2020 | 1111 | 0.030 |
Why?
|
Child | 3 | 2020 | 30492 | 0.030 |
Why?
|
Adenoma | 1 | 2019 | 745 | 0.030 |
Why?
|
Comorbidity | 1 | 2019 | 2439 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2020 | 969 | 0.030 |
Why?
|
Young Adult | 2 | 2020 | 22108 | 0.020 |
Why?
|
Age Factors | 1 | 2020 | 5520 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 4507 | 0.020 |
Why?
|
Adolescent | 2 | 2020 | 32663 | 0.020 |
Why?
|
Immunotherapy | 1 | 2022 | 3545 | 0.020 |
Why?
|
Quality of Life | 1 | 2020 | 4749 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2021 | 31042 | 0.010 |
Why?
|